Non-profit · founded 1968

Biomedical Research Institute

Rockville, United States · afbr-bri.org

Manage this page

Citations, last 5 years: 202
Works, last 5 years: 27
h-index: 112
Scientists listed: 1
Grants since 2016: 36

Grants received

2023–2025 · contract · N01

Task C16: Production and Development of Schistosomiasis Research Reagents

Margaret Mentink-Kane · Biomedical Research Institute · funded by National Institutes of Health

$1.7M

2023–2028 · research · R01

Broadly neutralizing SARS-CoV-2 peptidic knobs

Vaughn Vasil Smider · Biomedical Research Institute · funded by National Institutes of Health

$967.2kMonoclonal and Polyclonal Antibodies Research

2023–2024 · contract · N01

Task C16: Production and Development of Schistosomiasis Research Reagents

Margaret Mentink-Kane · Biomedical Research Institute · funded by National Institutes of Health

$1.6M

2023–2028 · research · R01

Broadly neutralizing SARS-CoV-2 peptidic knobs

Vaughn Vasil Smider · Biomedical Research Institute · funded by National Institutes of Health

$921kMonoclonal and Polyclonal Antibodies Research

2023–2028 · research · R01

Broadly neutralizing SARS-CoV-2 peptidic knobs

Vaughn Vasil Smider · Biomedical Research Institute · funded by National Institutes of Health

$921k

2023–2026 · contract · N01

Task C16: Production and Development of Schistosomiasis Research Reagents

Margaret Mentink-Kane · Biomedical Research Institute · funded by National Institutes of Health

$1.9M

2020–2022 · research · R21

Ultralong CDR3 antibodies targeting exhausted T cells

Vaughn Vasil Smider · Biomedical Research Institute · funded by National Institutes of Health

$303.5k

2020–2023 · research · R21

Ultralong CDR3 antibodies targeting exhausted T cells

Vaughn Vasil Smider · Biomedical Research Institute · funded by National Institutes of Health

$234.5k

2019–2024 · research · R01

Novel vaccine strategies to induce V2 apex-directed broad neutralizing antibodies

Laurent Karl Verkoczy · Biomedical Research Institute · funded by National Institutes of Health

$1.1MHIV Research and Treatment

2019–2023 · research · R01

Macrophage Migration Inhibitory Factor mediates bladder pain

Pedro L Vera · Biomedical Research Institute · funded by National Institutes of Health

$199.1kMacrophage Migration Inhibitory Factor

2019–2020 · contract · N01

Task C03: MAINTENANCE, DEVELOPMENT AND PRODUCTION OF SCHISTOSOMIASIS PARASITES, AND REAGENTS

Margaret Kane · Biomedical Research Institute · funded by National Institutes of Health

$1.3M

2019–2021 · contract · N01

Task C03: MAINTENANCE, DEVELOPMENT AND PRODUCTION OF SCHISTOSOMIASIS PARASITES, AND REAGENTS

Margaret Kane · Biomedical Research Institute · funded by National Institutes of Health

$1.4M

2019–2023 · research · R01

Macrophage Migration Inhibitory Factor mediates bladder pain

Pedro L Vera · Biomedical Research Institute · funded by National Institutes of Health

$273.9kMacrophage Migration Inhibitory Factor

2019–2023 · contract · N01

Task C03: MAINTENANCE, DEVELOPMENT AND PRODUCTION OF SCHISTOSOMIASIS PARASITES, AND REAGENTS

Margaret Kane · Biomedical Research Institute · funded by National Institutes of Health

$1.4M

2019–2024 · research · R01

Macrophage Migration Inhibitory Factor mediates bladder pain

Pedro L Vera · Biomedical Research Institute · funded by National Institutes of Health

$279.2kMacrophage Migration Inhibitory Factor

2019–2024 · research · R01

Novel vaccine strategies to induce V2 apex-directed broad neutralizing antibodies

Laurent Karl Verkoczy · Biomedical Research Institute · funded by National Institutes of Health

$957.5kHIV Research and Treatment

2019–2023 · research · R01

Macrophage Migration Inhibitory Factor mediates bladder pain

Pedro L Vera · Biomedical Research Institute · funded by National Institutes of Health

$207.2kMacrophage Migration Inhibitory Factor

2019–2025 · research · R01

Novel vaccine strategies to induce V2 apex-directed broad neutralizing antibodies

Laurent Karl Verkoczy · Biomedical Research Institute · funded by National Institutes of Health

$945.7kHIV Research and Treatment

2019–2020 · contract · N01

Task C03: MAINTENANCE, DEVELOPMENT AND PRODUCTION OF SCHISTOSOMIASIS PARASITES, AND REAGENTS

Margaret Kane · Biomedical Research Institute · funded by National Institutes of Health

$1.3M

2018–2019 · contract · N01

Task C03: MAINTENANCE, DEVELOPMENT AND PRODUCTION OF SCHISTOSOMIASIS PARASITES, AND REAGENTS

Margaret Mentink-Kane · Biomedical Research Institute · funded by National Institutes of Health

$1.3M

2017–2022 · research · R01

Defining clinically relevant viral epitopes with cow antibodies

Vaughn Vasil Smider · Biomedical Research Institute · funded by National Institutes of Health

$360k

2017–2024 · contract · N01

ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT

(Contact) · Biomedical Research Institute · funded by National Institutes of Health

$3 500

2017–2022 · research · R01

Therapeutic Exploitation of IPSE, a Urogenital Parasite-Derived Host Modulatory Protein, for Bladder Hypersensitivity Syndromes

Michael Harrison Hsieh · Biomedical Research Institute · funded by National Institutes of Health

$515.9k

2017–2022 · research · R01

Defining clinically relevant viral epitopes with cow antibodies

Vaughn Vasil Smider · Biomedical Research Institute · funded by National Institutes of Health

$358.6k

2017–2019 · research · R01

Therapeutic Exploitation of IPSE, a Urogenital Parasite-Derived Host Modulatory Protein, for Bladder Hypersensitivity Syndromes

Michael Harrison Hsieh · Biomedical Research Institute · funded by National Institutes of Health

$299.8k

2017–2024 · research · R01

Defining clinically relevant viral epitopes with cow antibodies

Vaughn Vasil Smider · Biomedical Research Institute · funded by National Institutes of Health

$352.9k

2017–2018 · contract · N01

TASK D16: MAINTENANCE, DEVELOPMENT AND PRODUCTION OF SCHISTOSOMIASIS PARASITES, REAGENTS AND ASSAYS

Michael Hsieh · Biomedical Research Institute · funded by National Institutes of Health

$523.5k

2017–2022 · research · R01

Therapeutic Exploitation of IPSE, a Urogenital Parasite-Derived Host Modulatory Protein, for Bladder Hypersensitivity Syndromes

Michael Harrison Hsieh · Biomedical Research Institute · funded by National Institutes of Health

$531.8k

2016–2020 · research · R01

An Orally Bioavailable Drug Candidate for Spinal Muscular Atrophy

Peter G Schultz · Biomedical Research Institute · funded by National Institutes of Health

$488.3kNeurogenetic and Muscular Disorders Research

2016–2021 · research · R01

CAR-T cell control through orthogonal antibody-based switches

Travis Scott Young · Biomedical Research Institute · funded by National Institutes of Health

$419.7kCAR-T cell therapy research

2016–2017 · contract · N01

Task D3:Maintenance, Development and Production of Schistosomiasis Parasites, Reagents and Assays

Michael Hsieh · Biomedical Research Institute · funded by National Institutes of Health

$1.6M

2014–2022 · research · R01

Molecular and Structural Studies of Antibody Diversity Mechanisms

Vaughn Vasil Smider · Biomedical Research Institute · funded by National Institutes of Health

$385.8kMonoclonal and Polyclonal Antibodies Research

2014–2022 · research · R01

Molecular and Structural Studies of Antibody Diversity Mechanisms

Vaughn Vasil Smider · Biomedical Research Institute · funded by National Institutes of Health

$290.7kMonoclonal and Polyclonal Antibodies Research

2014–2023 · research · R01

Molecular and Structural Studies of Antibody Diversity Mechanisms

Vaughn Vasil Smider · Biomedical Research Institute · funded by National Institutes of Health

$399.4kMonoclonal and Polyclonal Antibodies Research

2014–2022 · research · R01

Molecular and Structural Studies of Antibody Diversity Mechanisms

Vaughn Vasil Smider · Biomedical Research Institute · funded by National Institutes of Health

$399.4kMonoclonal and Polyclonal Antibodies Research

2010–2023 · research · R01

Defining parameters to induce breadth in knockin mice expressing HIV bnAb precursors

Laurent Karl Verkoczy · Biomedical Research Institute · funded by National Institutes of Health

$278.5kHIV Research and Treatment